





**Test Name** 

Age/Gender UHID/MR No : 34 Y 9 M 29 D/M

Visit ID

: CMAN.0000086775 : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399

Collected

: 18/Mar/2023 08:01AM

Received

: 18/Mar/2023 12:31PM : 18/Mar/2023 02:18PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF HAEMATOLOGY** ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324 Unit Result Bio. Ref. Range Method

HAEMOGLOBIN	16.3	g/dL	13-17	Spectrophotometer
PCV	48.40	%	40-50	Electronic pulse & Calculation
RBC COUNT	4.94	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	98	fL	83-101	Calculated
MCH	33.1	pg	27-32	Calculated
MCHC	33.8	g/dL	31.5-34.5	Calculated
R.D.W	13.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,840	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)			
NEUTROPHILS	45	%	40-80	Electrical Impedance
LYMPHOCYTES	42.7	%	20-40	Electrical Impedance
EOSINOPHILS	3.3	%	1-6	Electrical Impedance
MONOCYTES	8.3	%	2-10	Electrical Impedance
BASOPHILS	0.7	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2628	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	2493.68	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	192.72	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	484.72	Cells/cu.mm	200-1000	Electrical Impedance
BASOPHILS	40.88	Cells/cu.mm	0-100	Electrical Impedance
PLATELET COUNT	190000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	11	mm at the end of 1 hour	0-15	Modified Westergre

RBC NORMOCYTIC NORMOCHROMIC

WBC WITHIN NORMAL LIMITS

PLATELETS ARE ADEQUATE ON SMEAR

NO HEMOPARASITES SEEN

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE

Page 1 of 12

SIN No:BED230068620











Age/Gender

: 34 Y 9 M 29 D/M

UHID/MR No Visit ID : CMAN.0000086775 : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399 Collected

: 18/Mar/2023 08:01AM

Received

: 18/Mar/2023 12:31PM

Reported

: 18/Mar/2023 05:20PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	HAEMATOLOG	Υ	
ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALE	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTOR,	WHOLE BLOOD-EDTA	
BLOOD GROUP TYPE	0	Microplate technology
Rh TYPE	Positive	Microplate technology

Page 2 of 12



SIN No:BED230068620









Age/Gender : 34 Y 9 M 29 D/M
UHID/MR No : CMAN.0000086775
Visit ID : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399 Collected : 18/Mar/2023 08:01AM

Received : 18/Mar/2023 12:07PM Reported : 18/Mar/2023 03:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

			777.55.65	
	DEPARTMENT OF	BIOCHEMISTR	Υ	
ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, FASTING, NAF PLASMA 129	mg/dL	70-100	HEXOKINASE
----------------------------------	-------	--------	------------

## **Comment:**

As per American Diabetes Guidelines

Fasting Glucose Values in mg/d L	Interpretation	
<100 mg/dL	Normal	
100-125 mg/dL	Prediabetes	
≥126 mg/dL	Diabetes	

GLUCOSE, POST PRANDIAL (PP), 2	240	mg/dL	70-140	HEXOKINASE	
HOURS , NAF PLASMA					

#### **Comment:**

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Ref: Marks medical biochemistry and clinical approach

HBA1C, GLYCATED HEMOGLOBIN,	9.0	%	HPLC
WHOLE BLOOD-EDTA			
ESTIMATED AVERAGE GLUCOSE (eAG),	212	mg/dL	Calculated
WHOLE BLOOD-EDTA			

# **Comment:**

Reference Range as per American Diabetes Association (ADA):

REFERENCE GROUP	HBA1C IN %
NON DIABETIC ADULTS > 18 YEARS	<5.7

Page 3 of 12









Age/Gender

: 34 Y 9 M 29 D/M

UHID/MR No Visit ID : CMAN.0000086775 : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399 Collected : 18/Mar/2023 08:01AM

Received : 18/Mar/2023 12:07PM Reported : 18/Mar/2023 03:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

	DEPARTMENT OF	BIOCHEMISTR	Υ	
ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALE	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

AT RISK (PREDIABETES)	5.7 - 6.4
DIAGNOSING DIABETES	≥ 6.5
DIABETICS	
· EXCELLENT CONTROL	6 – 7
· FAIR TO GOOD CONTROL	7 – 8
· UNSATISFACTORY CONTROL	8 – 10
· POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
- 2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
- 3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control







Age/Gender : 34 Y 9 M 29 D/M UHID/MR No : CMAN.0000086775 Visit ID : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399

Collected : 18/Mar/2023 08:01AM

Received : 18/Mar/2023 12:07PM Reported : 18/Mar/2023 03:14PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY
----------------------------


Unit Bio. Ref. Range Method **Test Name** Result

# Chromatogram Report

2023-03-18 12:27:39 1234 V5. 29 1234 ID EDT230028189 Sample No. 03180063 SL 0002 - 02 Patient ID Name Comment

> Y =1. 1676X + 0. 6473 CALIB Name Area Time 0. 25 0.6 12.89 A1A 0. 32 0. 39 0. 48 0. 60 A1B F 0.5 11.57 1.5 2.1 9.0 32.00 LA1C+ SA1C 44. 05 151. 47 1885. 26 A<sub>0</sub> 89.6 0.89 H-VO H-V1 H-V2

2137. 24 HbA1c 9.0 % HbA1 10.2 % HbF 1.5 %



18-03-2023 12:27:39 apollo

APOLLO DIAGNOSTICS GLOBAL BALNAGAR

1/1

Page 5 of 12



This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory, Hyderabad



Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744 APOLLO CLINICS NETWORK

Address:
Door No: 8-1-284/OU/439 & 8-1-284/OU/440, O. U. Colony, Manikonda
Road, Shaikpet,, Manikonda, Hyderabad, Telangana, India - 500008











Age/Gender UHID/MR No : 34 Y 9 M 29 D/M

Visit ID

: CMAN.0000086775 : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399 Collected

: 18/Mar/2023 08:01AM

Received

: 18/Mar/2023 12:21PM : 18/Mar/2023 02:39PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

# DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	170	mg/dL	<200	CHO-POD
TRIGLYCERIDES	234	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	40	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	130	mg/dL	<130	Calculated
LDL CHOLESTEROL	83.2	mg/dL	<100	Calculated
VLDL CHOLESTEROL	46.8	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.25		0-4.97	Calculated

#### **Comment:**

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

Page 6 of 12

SIN No:SE04323659









Age/Gender UHID/MR No : 34 Y 9 M 29 D/M

Visit ID

: CMAN.0000086775 : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399

Collected

Reported

: 18/Mar/2023 08:01AM

Received : 18/Mar/2023 12:21PM

: 18/Mar/2023 02:39PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY							
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method			

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.74	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.10	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.64	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	45	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	28.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	87.00	U/L	30-120	IFCC
PROTEIN, TOTAL	8.35	g/dL	6.6-8.3	Biuret
ALBUMIN	4.79	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.56	g/dL	2.0-3.5	Calculated
A/G RATIO	1.35		0.9-2.0	Calculated

Page 7 of 12



SIN No:SE04323659









Age/Gender UHID/MR No : 34 Y 9 M 29 D/M

Visit ID

: CMAN.0000086775 : CMANOPV165454

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : 123399

Collected

: 18/Mar/2023 08:01AM

Received

: 18/Mar/2023 12:21PM

Reported

: 18/Mar/2023 02:39PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) , SERUM						
CREATININE	0.96	mg/dL	0.84 - 1.25	Modified Jaffe, Kinetic		
UREA	19.90	mg/dL	17-43	GLDH, Kinetic Assay		
BLOOD UREA NITROGEN	9.3	mg/dL	8.0 - 23.0	Calculated		
URIC ACID	5.27	mg/dL	3.5–7.2	Uricase PAP		
CALCIUM	10.22	mg/dL	8.8-10.6	Arsenazo III		
PHOSPHORUS, INORGANIC	2.35	mg/dL	2.5-4.5	Phosphomolybdate Complex		
SODIUM	134	mmol/L	136–146	ISE (Indirect)		
POTASSIUM	4.0	mmol/L	3.5–5.1	ISE (Indirect)		
CHLORIDE	100	mmol/L	101–109	ISE (Indirect)		

Page 8 of 12



SIN No:SE04323659







Age/Gender UHID/MR No : 34 Y 9 M 29 D/M

Visit ID

: CMAN.0000086775 : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399

Collected

: 18/Mar/2023 08:01AM

Received

: 18/Mar/2023 12:21PM : 18/Mar/2023 02:39PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

# **DEPARTMENT OF BIOCHEMISTRY**

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	22.00	U/L	<55	IFCC	
(GGT), SERUM					

Page 9 of 12

SIN No:SE04323659

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)











Age/Gender : 34 Y 9 M 29 D/M UHID/MR No : CMAN.0000086775

Visit ID : CMANOPV165454

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 123399

Collected : 18/Mar/2023 08:01AM

Received : 18/Mar/2023 12:21PM Reported : 18/Mar/2023 02:54PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF IMMUNOLOGY					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

THYROID PROFILE (TOTAL T3, TOTAL T4, TSH), SERUM				
TRI-IODOTHYRONINE (T3, TOTAL)	1	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	7.82	μg/dL	6.09-12.23	CLIA
THYROID STIMULATING HORMONE (TSH)	1.874	μIU/mL	0.34-5.60	CLIA

## **Comment:**

Serum TSH concentrations exhibit a diurnal variation with the peak occurring during the night and the nadir occurring between 10 a.m. and 4 p.m.In primary hypothyroidism, thyroid-stimulating hormone (TSH) levels will be elevated. In primary hyperthyroidism, TSH levels will be low. Elevated or low TSH in the context of normal free thyroxine is often referred to as subclinical hypo- or hyperthyroid-ism, respectively. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.


Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.

## Note:

IFOR PROGRAM TOMOLOG	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

Page 10 of 12













**Test Name** 

Age/Gender

: 34 Y 9 M 29 D/M

UHID/MR No Visit ID

: CMAN.0000086775

Ref Doctor

: CMANOPV165454

: Dr.SELF Emp/Auth/TPA ID : 123399

Collected

: 18/Mar/2023 08:01AM

Received

: 18/Mar/2023 12:31PM : 18/Mar/2023 01:37PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF CLINICAL PATHOLOGY** ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324 Unit Result Bio. Ref. Range Method

COMPLETE URINE EXAMINATION, URINE				
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	5.5		5-7.5	Bromothymol Blue
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUNT	AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 11 of 12



SIN No:UR2080108









Patient Name

: Mr.SHASHANKA SEKAHR BEHERA

Age/Gender UHID/MR No : 34 Y 9 M 29 D/M

Visit ID

: CMAN.0000086775

Ref Doctor

: CMANOPV165454

Emp/Auth/TPA ID

: Dr.SELF : 123399

Collected

: 18/Mar/2023 08:01AM

**NEGATIVE** 

Received

: 18/Mar/2023 12:31PM : 18/Mar/2023 02:56PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

# ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Tost Namo	Pocult	Unit	Rio Pof Pango	N/

Method Result Bio. Ref. Range

URINE GLUCOSE(POST PRANDIAL) POSITIVE (+++)

**NEGATIVE** Dipstick

**URINE GLUCOSE(FASTING)** 

**NEGATIVE** 

Dipstick

\*\*\* End Of Report \*\*\*

Result/s to Follow: PERIPHERAL SMEAR

DR. SHALINI SINGH M.B.B.S, MD

Consultant Pathologist

Dr.SRINIVAS N.S.NORI M.B.B.S, NO (PATHOLOGY) Consultant Pathologist

M.B.B.S, M.D(Pathology) Consultant Pathologist

Dr E.Maruthi Prasad MSc, PhD (Biochemistry) Consultant Biochemist

Page 12 of 12





: CMANOPV165454

: 20-03-2023 11:58

Patient Name : Mr. SHASHANKA SEKAHR BEHERA Age/Gender : 34 Y/M

UHID/MR No. : Complete Collected on :

: CMAN.0000086775

775 OP Visit No

Reported on

**Ref Doctor** : SELF **Emp/Auth/TPA ID** : 123399

# DEPARTMENT OF RADIOLOGY

# X-RAY CHEST PA

Cardiac is normal in size.

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

# **CONCLUSION:**

No obvious abnormality seen

Dr. MD RAHEEMUDDIN QURESHI

Radiology



Patient Name : Mr. SHASHANKA SEKAHR BEHERA Age/Gender : 34 Y/M

**UHID/MR No.** : CMAN.0000086775 **OP Visit No** : CMANOPV165454

Sample Collected on : Reported on : 18-03-2023 12:47

**Ref Doctor** : SELF **Emp/Auth/TPA ID** : 123399

# DEPARTMENT OF RADIOLOGY

## **ULTRASOUND - WHOLE ABDOMEN**

<u>Liver</u> appears enlarge in size 15.09 cm and increased echotexture. No focal lesion is seen. PV and CBD normal. No dilatation of the intrahepatic biliary radicals.

<u>Gall bladder</u> is well distended. No evidence of calculus. Wall thickness appears normal. No evidence of periGB collection. No evidence of focal lesion is seen.

Spleen appears normal in size 9.81 cm. No focal lesion seen. Splenic vein appears normal.

Pancreas appears normal in echopattern. No focal/mass lesion/calcification.

No evidence of peripancreatic free fluid or collection. Pancreatic duct appears normal.

**Both the kidneys** appear normal in size, shape and echopattern. Cortical thickness and CM differentiation are maintained. No calculus / hydronephrosis seen on either side.

Right kidney: 9.34 x 4.84 cm. Left kidney: 10.13 x 6.11 cm.

<u>Urinary Bladder</u> is well distended and appears normal. No evidence of any wall thickening or abnormality. No evidence of any intrinsic or extrinsic bladder abnormality detected.

**Prostate** is normal in size 2.90 x 2.92 x 3.17 cm and echo texture" volume measuring 14.06 ml. .No evidence of necrosis/calcification seen.

# **IMPRESSION:-**

#### MILD HEPATOMEGALY WITH FATTY LIVER.

# Suggest - clinical correlation.

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.





**Patient Name** 

: Mr. SHASHANKA SEKAHR BEHERA

Age/Gender

: 34 Y/M

Dr. MD RAHEEMUDDIN QURESHI

Radiology



## LETTER OF APPROVAL / RECOMMENDATION

To,

The Coordinator,
Mediwheel (Arcofemi Healthcare Limited)
Helpline number: 011- 41195959

Dear Sir / Madam,

# Sub: Annual Health Checkup for the employees of Bank of Baroda

This is to inform you that the following employee wishes to avail the facility of Cashless Annual Health Checkup provided by you in terms of our agreement.

PARTICULARS	EMPLOYEE DETAILS
NAME	MR. BEHERA SHASHANKA SEKHAR
EC NO.	123399
DESIGNATION	LINK IMPLEMENTATION
PLACE OF WORK	HYDERABAD, DISASTER RECOVERY SI
BIRTHDATE	20-05-1988
PROPOSED DATE OF HEALTH	18-03-2023
CHECKUP	
BOOKING REFERENCE NO.	22M123399100049066E

This letter of approval / recommendation is valid if submitted along with copy of the Bank of Baroda employee id card. This approval is valid from 15-03-2023 till 31-03-2023 The list of medical tests to be conducted is provided in the annexure to this letter. Please note that the said health checkup is a cashless facility as per our tie up arrangement. We request you to attend to the health checkup requirement of our employee and accord your top priority and best resources in this regard. The EC Number and the booking reference number as given in the above table shall be mentioned in the invoice, invariably.

We solicit your co-operation in this regard.

Yours faithfully,

Sd/-

Chief General Manager HRM Department Bank of Baroda

(Note: This is a computer generated letter. No Signature required. For any clarification, please contact Mediwheel (Arcofemi Healthcare Limited))